Search
Deshengji's Novel KRAS G12C Therapy Receives FDA Breakthrough Therapy Designation
2025-08-29 /
Read about 0 minute
Author：小编
Deshengji's flagship candidate, D3S-001, is progressing through multiple clinical trials, encompassing both monotherapy and combination therapy across various stages of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). D3S-001 exhibits robust binding to KRAS G12C, characterized by swift target engagement, and its inhibitory action remains unperturbed by epidermal growth factor (EGF) and hepatocyte growth factor (HGF). This esteemed Breakthrough Therapy Designation by the Food and Drug Administration (FDA) will catalyze D3S-001's global clinical development trajectory and establish a new benchmark for domestic innovative pharmaceuticals.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
